JKB-122
JKB-122 is an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis and nonalcoholic fatty liver disease.[1] The drug was transferred to Biostax in 2022.[2][3][4][5]
References[edit]
- ^ Hsu, Mei-Chi; Liu, Sheng-Hung; Wang, Chiung-Wen; Hu, Nai-Yun; Wu, Edwin S.C.; Shih, Ying-Chu; Chiu, Peter J.S. (October 2017). "JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis". European Journal of Pharmacology. 812: 113–120. doi:10.1016/j.ejphar.2017.07.012. PMID 28694068. S2CID 30160157.
- ^ "Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH". BioSpace. Retrieved 2 December 2023.
- ^ Doycheva, Iliana; Watt, Kymberly D.; Gulamhusein, Aliya F. (June 2019). "Autoimmune hepatitis: Current and future therapeutic options". Liver International. 39 (6): 1002–1013. doi:10.1111/liv.14062. PMID 30716203.
- ^ Anwar, Muhammad Ayaz; Shah, Masaud; Kim, Jason; Choi, Sangdun (May 2019). "Recent clinical trends in Toll-like receptor targeting therapeutics". Medicinal Research Reviews. 39 (3): 1053–1090. doi:10.1002/med.21553. ISSN 0198-6325. PMC 6587958. PMID 30450666.
- ^ Jefremow, André; Neurath, Markus F. (October 2021). "New agents for immunosuppression". Best Practice & Research Clinical Gastroenterology. 54–55: 101763. doi:10.1016/j.bpg.2021.101763. PMID 34874846. S2CID 245025631.